AstraZeneca Shares Decline After FDA Panel Votes Against Camizestrant

By Stocks News   |   6 months ago   |   Stock Market News
AstraZeneca Shares Decline After FDA Panel Votes Against Camizestrant

AstraZeneca (NYSE: AZN) shares fell Friday after advisers to the U.S. Food and Drug Administration voted against recommending approval of camizestrant, the company’s experimental oral drug for a form of breast cancer.

The advisory committee voted 6-3 against the drug late Thursday, citing concerns about the design of the trial used to support the application. The FDA typically considers the recommendations of its advisory panels in its reviews, though it is not required to follow them.

The vote centered on AstraZeneca’s Phase 3 SERENA-6 trial, which was presented in 2025. The study showed a 56% reduction in the risk of disease progression or death compared with standard care, according to the company.

Panel members who opposed approval were not persuaded that switching patients to camizestrant earlier in treatment improved long-term survival outcomes versus other treatment approaches. The panel did not raise major concerns about the drug’s overall safety or toxicity, according to analysts reviewing the meeting.

AstraZeneca’s London-listed shares declined 2% in morning trading after the vote. The stock has gained about 25% over the past 12 months, compared with a 20% rise for the FTSE 100.

Barclays analyst James Gordon said the vote was negative for the drug’s near-term regulatory path but did not amount to a rejection of camizestrant’s potential. He said the panel’s concern was whether the SERENA-6 trial proved that acting on tumor detection before radiographic progression improves long-term patient outcomes.

Jefferies analysts said doctors on the panel questioned whether the data supported an early change in therapy, noting concerns that accelerating the treatment sequence could reduce time on other effective options. The analysts said SERENA-6 represented only a small portion of AstraZeneca’s $80 billion 2030 sales target and was not central to their Buy rating on the stock.

AstraZeneca said it would continue working with the FDA as the agency completes its review of the camizestrant application. Susan Galbraith, executive vice president of oncology hematology research and development, said the company still believes strongly in the drug.

The company has reported several positive data readouts in recent months and expects 11 additional readouts in 2026.

About AstraZeneca

AstraZeneca (NYSE: AZN) is a global biopharmaceutical company founded in 1999 through the merger of Astra AB and Zeneca Group. The company is headquartered in Cambridge, England.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article. 

 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer